Twist Bioscience (NASDAQ:TWST) Stock Price Target Lowered at Leerink Partners

Twist Bioscience (NASDAQ:TWST) had its price objective decreased by stock analysts at Leerink Partners from $190.00 to $175.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s target price suggests a potential upside of 54.97% from the company’s previous close.

TWST has been the subject of several other reports. UBS Group started coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective for the company. Guggenheim lifted their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Robert W. Baird cut their price target on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Finally, Canaccord Genuity Group decreased their target price on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $143.64.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $1.29 during mid-day trading on Friday, hitting $112.93. The stock had a trading volume of 1,582,465 shares, compared to its average volume of 1,787,548. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company’s 50 day simple moving average is $150.57 and its 200 day simple moving average is $92.73. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of -50.92 and a beta of 2.25. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $219.71.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $126.64 million during the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience’s quarterly revenue was up 26.7% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience will post -2.11 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other news, CEO Emily Leproust sold 4,573 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $619,184.20. Following the completion of the transaction, the chief executive officer directly owned 558,187 shares in the company, valued at approximately $75,578,519.80. This represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of the company’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $156.30, for a total value of $384,810.60. Following the completion of the transaction, the chief financial officer directly owned 98,114 shares of the company’s stock, valued at approximately $15,335,218.20. The trade was a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 495,279 shares of company stock worth $80,489,387 in the last ninety days. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $600,191,000. William Blair Investment Management LLC bought a new stake in Twist Bioscience during the second quarter worth $223,722,000. Bank of America Corp DE bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $94,922,000. Stephens Investment Management Group LLC raised its stake in shares of Twist Bioscience by 1.7% in the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock valued at $150,808,000 after buying an additional 13,055 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience in the first quarter valued at approximately $22,563,000.

Top Twist Bioscience Stories

Here are a few of the latest stories about TWST:

• Positive Sentiment: TD Cowen and Robert W. Baird maintained Buy and Outperform ratings, respectively, despite cutting their price targets to $137 and $135. Both targets imply upside from the roughly $114 reference price. TD Cowen price target update Baird price target update
• Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is slightly above the $549 million consensus, but the narrow margin may have disappointed investors looking for a stronger outlook. Coverage of the outlook
• Negative Sentiment: The earnings beat did not prevent a negative market reaction: coverage pointed to an underwhelming fiscal 2027 outlook and ongoing cost pressure as concerns. The target cuts—from $190 to $137 at TD Cowen and $187 to $135 at Baird—may also weigh on sentiment, even though both firms kept positive ratings. Earnings and market reaction

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.